COPD Management Alternatives to Breztri

Introduction to Alternative Therapies

The American Thoracic Society recommends considering other triple therapy combinations (ICS/LAMA/LABA) in single or multiple inhalers for patients with severe COPD (GOLD category D) 1, 2
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests fluticasone/umeclidinium/vilanterol (Trelegy Ellipta) as an alternative single-inhaler triple therapy option for patients with moderate to severe COPD with persistent symptoms and high exacerbation risk 3
Beclomethasone/glycopyrronium/formoterol is another single-inhaler triple therapy alternative for patients with FEV₁ <50% predicted and history of exacerbations, according to the European Respiratory Society 4

The American College of Chest Physicians recommends LAMA/LABA combinations (e.g., umeclidinium/vilanterol, glycopyrronium/formoterol, tiotropium/olodaterol) as appropriate alternatives for patients with less severe disease or those who cannot tolerate ICS 1, 2
The European Respiratory Society suggests ICS/LABA combinations (e.g., fluticasone/salmeterol, budesonide/formoterol) for patients with features of asthma-COPD overlap or high blood eosinophil counts 2, 5
Long-acting muscarinic antagonists (LAMAs) such as tiotropium, umeclidinium, or glycopyrronium can be used as monotherapy in patients with milder disease (GOLD Group A or B), as recommended by the American Thoracic Society 1, 2

For patients with high exacerbation risk (≥2 exacerbations/year or ≥1 hospitalization), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends triple therapy or LAMA/LABA 1, 3
The American College of Chest Physicians suggests considering ICS-containing regimens for patients with blood eosinophil counts ≥150 cells/mm³ 6, 5
For patients with chronic bronchitis and FEV₁ <50% predicted, the American Thoracic Society recommends considering adding roflumilast to current therapy if still experiencing exacerbations 1, 2

The European Respiratory Society notes that pneumonia risk is higher with ICS-containing regimens (NNH of 33 patients treated for one year), which should be considered when selecting therapy 4
Patients with cardiovascular comorbidities should be monitored carefully when using LABA-containing medications, as recommended by the American College of Chest Physicians 7, 5

The American Thoracic Society recommends assessing COPD severity and exacerbation history to guide treatment decisions, with options including LAMA or LABA monotherapy for low symptom burden (GOLD A) 1, 2
For moderate symptoms (GOLD B), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests LAMA/LABA dual therapy 1, 2
For high exacerbation risk (GOLD C/D), the American College of Chest Physicians recommends LAMA/LABA or triple therapy 1, 2, 3

The American Thoracic Society warns that discontinuing ICS abruptly in patients with asthma-COPD overlap can lead to deterioration 1, 2
Failing to reassess therapy effectiveness after switching medications is a common pitfall, as noted by the American College of Chest Physicians 1
Not considering comorbidities when selecting alternative therapies is another pitfall, as recommended by the European Respiratory Society 7, 5